NCT05367700 - A Study of HS-10382 in Patients With Chronic Myeloid Leukemia. | Biotech Hunter

Enrollment

108

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

September 30, 2026

Conditions

CML, Chronic PhaseCML, Accelerated Phase

Interventions

DRUG

HS-10382(Part 1: Dose escalation)

Single or multiple dose(s) of HS-10382 once daily.

DRUG

HS-10382(Part 2: Dose expansion)

HS-10382 is administered orally once daily.

Trial Locations (1)

RECRUITING

Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan